Caplin Point Labs acquires 10 ANDAs, targets $473M US market
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The facility will manufacture tablets, capsules, and injections for the oncology segment
The inspection classification was determined by the agency as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated